NetworkNewsBreaks Archive - Page 321 of 2095

ThursdayJun 20, 2024 12:21 pm

NetworkNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Significant Progress on Destino Ranch Project

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today provided an update on its premier project, Destino Ranch, which is being developed by the company’s entertainment division through its wholly owned subsidiary, Lavish Entertainment. Destino Ranch is a bold project led by Lavish, designed to provide a unique combination of world-class entertainment, opulent accommodations and immersive experiences. Lavish has made significant progress in developing Destino Ranch over the past six months, including a massive overhaul of the irrigation system and extensive cleanup efforts including the repair of perimeter fencing, reinstallation of gates, and opening of roadways around the project. Tree care has…

ThursdayJun 20, 2024 11:33 am

NetworkNewsBreaks – Fathom Nickel Inc. (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF) Receives New Exploration Permit, Commences Exploration Field Activities at the Gochager Lake Project

Fathom Nickel (CSE: FNI) (FSE: 6Q5) (OTCQB: FNICF), focused on the exploration for nickel, cobalt and copper in north-central Saskatchewan, today announced the recent receipt of all necessary permits to continue exploration activity at its Gochager Lake project. The company also announced the commencement of exploration field activities at the project, with field crews already mobilized. According to the announcement, the exploration permit, which expires July 31, 2026, allows Fathom to drill up to 60 drillholes; construct and utilize an all-season 25-person camp; do necessary line-cutting ahead of surface geophysical surveys; and prepare necessary ground and ice trails to facilitate the…

ThursdayJun 20, 2024 11:05 am

NetworkNewsBreaks – HUB Cyber Security Ltd. (NASDAQ: HUBC) Provides Statement Regarding Settlement with Oppenheimer & Co.

HUB Cyber Security (NASDAQ: HUBC) (“HUB Security”), a developer of confidential computing cybersecurity solutions and services, has released a statement regarding recent press reports about a settlement with Oppenheimer & Co. The statement reads, “The company confirms that it is making progress towards reaching a settlement regarding a $12 million dispute. The settlement process is moving forward with Oppenheimer & Co. to resolve the claims related to unpaid fees for SPAC merger-related services.” To view the full press release, visit https://nnw.fm/hX2R1 About HUB Security Ltd. HUB Cyber Security (“HUB Security”) was established in 2017 by veterans of the elite intelligence…

ThursdayJun 20, 2024 11:01 am

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Shares Update on Its AVERSA(TM) Fentanyl Product Development Program

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, today provided an update on its AVERSA(TM) Fentanyl product development program. This comes as the company plans to complete scale-up of the commercial manufacturing process and move towards the single Phase 1 human abuse potential study prior to a New Drug Application (“NDA”) filing. According to the update, Nutriband is currently working with its partner Kindeva Drug Delivery to develop the commercial scale manufacturing process for the final product, which will incorporate Nutriband’s AVERSA(TM) abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. The update noted…

ThursdayJun 20, 2024 9:38 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Presents Extended Survival Data to Support CNM-Au8® as Potential Treatment for ALS at 2024 ENCALS Meeting

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, presented new long-term CNM-Au8 treatment results for survival and neurofilament light (“NfL”) levels from the HEALEY ALS Platform Trial open label extension (“OLE”) at the European Network for the Cure of ALS (“ENCALS”) meeting in Stockholm, Sweden. Entitled “Long-Term CNM-Au8 Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” the presentation data highlights up to 42 months (3.5 years) of survival…

ThursdayJun 20, 2024 8:30 am

NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Calls Meeting a ‘Milestone’ as FDA Affirms Alignment

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has received formal minutes from its pre-New Drug Application (“NDA”) Type-B Chemistry, Manufacturing, and Controls (“CMC”) meeting with the U.S. Food and Drug Administration (“FDA”). Tonix met with the FDA regarding its product candidate Tonmya(TM), also known as TNX-102 SL, for the management of fibromyalgia. According to the announcement, the meeting was for Tonix Pharmaceuticals officials to identify alignment and agreement with the FDA on key CMC topics as the company prepared to submit an NDA to the FDA. “We remain encouraged…

TuesdayJun 18, 2024 3:17 pm

NetworkNewsBreaks – Trump Media & Technology Group Corp. (NASDAQ: DJT) Stock Faces Challenges Amid Reaudited Finances

Trump Media & Technology Group (NASDAQ: DJT) has recently faced challenges, notably a significant drop in its stock price. This downturn is linked to the company’s announcement of reaudited finances and the appointment of a new auditor, following issues with the previous one. Trump Media, owned by former President Donald Trump, operates in the competitive social media landscape, contending with giants like Facebook and Twitter for user engagement and advertising revenue. The stock of Trump Media is currently trading at $30.8, marking a notable decrease of $3.92 or approximately 11.29%. This decline is significant, considering the stock’s performance over the past year, where it reached…

TuesdayJun 18, 2024 2:24 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction and more. “This study will be the most comprehensive and impactful GLP-1 investigation that Lexaria has ever undertaken,” said John Docherty, president of Lexaria. “The greatly expanded scope compared to our previous studies will allow us to investigate DehydraTECH-GLP-1 safety and efficacy over an extended treatment duration…

TuesdayJun 18, 2024 2:20 pm

NetworkNewsBreaks – Roth Capital Partners Continues Partnership with IBN as Official Marketing Partner for Annual ROTH London Conference

Roth Capital Partners (Roth MKM), a relationship-driven investment bank dedicated to serving growth companies and their investors, has once again selected IBN as an official marketing sponsor for this month’s upcoming ROTH London Conference. The event is scheduled for June 25–27, 2024, in London. This year marks the 10th annual gathering of the ROTH London Conference, and the event has become widely recognized for bringing experienced C-suite executives from innovative growth companies together with qualified investors to explore potential collaborations. According to the announcement, as an official marketing sponsor, IBN will leverage its comprehensive corporate communications capabilities to increase awareness…

TuesdayJun 18, 2024 2:15 pm

NetworkNewsBreaks – Gain Therapeutics Inc. (NASDAQ: GANX) Releases Pricing of Underwritten Public Offering, Projected to Reach $11M

Gain Therapeutics (NASDAQ: GANX), a clinical-stage biotechnology company leading the discovery and development of next-generation allosteric therapies, has announced the pricing of an underwritten public offering. The public offering is comprised of 7,116,547 shares of its common stock offered at $1.35 per share and prefunded warrants to purchase 1,031,602 shares of common stock in lieu of shares of common stock to certain investors. According to the announcement, the prefunded warrants will be immediately exercisable. In addition, the company granted the underwriter a 30-day option to purchase up to 1,222,222 additional shares of common stock at the public offering price, less underwriting…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks